AC
YMAB

Allstate Corporation’s Y-mAbs Therapeutics YMAB Stock Holding History

Allstate Corporation’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,394
Closed -$268K – 767
2021
Q3 		$268K Hold
9,394
– – 0.01% 651
2021
Q2 		$318K Buy
9,394
+2,455
+35% +$78.8K 0.01% 642
2021
Q1 		$210K Buy
6,939
+1,012
+17% +$41.5K 0.01% 709
2020
Q4 		$293K Hold
5,927
– – 0.01% 628
2020
Q3 		$228K Sell
5,927
-120
-2% -$4.78K 0.01% 625
2020
Q2 		$261K Buy
+6,047
New +$229K 0.01% 611

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Allstate Corporation's YMAB Position: Q4 2021 in Review

Allstate Corporation sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 9,394 shares — an estimated $268K sold.

Allstate Corporation first reported a position in YMAB in Q2 2020 and held it in 6 quarters. The position peaked at $318K in Q2 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Allstate Corporation reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Allstate Corporation sold 9,394 Y-mAbs Therapeutics shares in Q4 2021, an estimated $268K.
  • Allstate Corporation first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 6 quarters.
  • Allstate Corporation's Y-mAbs Therapeutics position peaked at $318K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Allstate Corporation's 13F filing for Q4 2021, filed 15 Feb 2022.